title: Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499.
authors: Fox Chase Cancer Center, Philadelphia, PA, USA.
authors: M R
authors: MR
authors: Smith
authors: Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
authors: F
authors: F
authors: Hong
authors: Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
authors: H
authors: H
authors: Li
authors: Northwestern University, Chicago, IL, USA.
authors: L I
authors: LI
authors: Gordon
authors: British Columbia Cancer Agency, Vancouver, BC, USA.
authors: R D
authors: RD
authors: Gascoyne
authors: Montefiore Medical Center, Bronx, NY, USA.
authors: E M
authors: EM
authors: Paietta
authors: Stanford University, Stanford, CA, USA.
authors: R H
authors: RH
authors: Advani
authors: University of Alabama, Birmingham, AL, USA.
authors: A
authors: A
authors: Forero-Torres
authors: Stanford University, Stanford, CA, USA.
authors: S J
authors: SJ
authors: Horning
authors: University of Wisconsin, Madison, WI, USA.
authors: B S
authors: BS
authors: Kahl
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000532:radiotherapy; D011241:Prednisone / Q000627:therapeutic use; D016499:Radioimmunotherapy / Q000379:methods; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; C422802:ibritumomab tiuxetan; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone